252 related articles for article (PubMed ID: 10520851)
1. Intestinal permeability test as a predictor of clinical course in Crohn's disease.
D'Incà R; Di Leo V; Corrao G; Martines D; D'Odorico A; Mestriner C; Venturi C; Longo G; Sturniolo GC
Am J Gastroenterol; 1999 Oct; 94(10):2956-60. PubMed ID: 10520851
[TBL] [Abstract][Full Text] [Related]
2. Predicting relapse in Crohn's disease: a biopsychosocial model.
Bitton A; Dobkin PL; Edwardes MD; Sewitch MJ; Meddings JB; Rawal S; Cohen A; Vermeire S; Dufresne L; Franchimont D; Wild GE
Gut; 2008 Oct; 57(10):1386-92. PubMed ID: 18390994
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of Crohn's disease following corticosteroid-induced remission.
Papi C; Festa V; Leandro G; Moretti A; Tanga M; Koch M; Capurso L
Am J Gastroenterol; 2007 Apr; 102(4):814-9. PubMed ID: 17222316
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
6. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
7. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.
Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
Aliment Pharmacol Ther; 2004 Mar; 19(6):671-8. PubMed ID: 15023169
[TBL] [Abstract][Full Text] [Related]
8. Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea.
Di Leo V; D'Incà R; Diaz-Granado N; Fries W; Venturi C; D'Odorico A; Martines D; Sturniolo GC
Am J Gastroenterol; 2003 Oct; 98(10):2245-52. PubMed ID: 14572575
[TBL] [Abstract][Full Text] [Related]
9. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission.
Garcia Vilela E; De Lourdes De Abreu Ferrari M; Oswaldo Da Gama Torres H; Guerra Pinto A; Carolina Carneiro Aguirre A; Paiva Martins F; Marcos Andrade Goulart E; Sales Da Cunha A
Scand J Gastroenterol; 2008; 43(7):842-8. PubMed ID: 18584523
[TBL] [Abstract][Full Text] [Related]
10. Is an increased intestinal permeability a valid predictor of relapse in Crohn disease?
Jørgensen J; Ranløv PJ; Bjerrum PJ; Diemer H; Bisgaard K; Elsborg L
Scand J Gastroenterol; 2001 May; 36(5):521-7. PubMed ID: 11346207
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse.
Treton X; Bouhnik Y; Mary JY; Colombel JF; Duclos B; Soule JC; Lerebours E; Cosnes J; Lemann M;
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):80-5. PubMed ID: 18849016
[TBL] [Abstract][Full Text] [Related]
12. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.
D'Incà R; Annese V; di Leo V; Latiano A; Quaino V; Abazia C; Vettorato MG; Sturniolo GC
Aliment Pharmacol Ther; 2006 May; 23(10):1455-61. PubMed ID: 16669960
[TBL] [Abstract][Full Text] [Related]
13. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Kim PS; Zlatanic J; Korelitz BI; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
[TBL] [Abstract][Full Text] [Related]
15. [Mean platelet volume (MPV) in Crohn's disease patients].
Douda T; Bures J; Rejchrt S; Kopácová M; Pecka M; Malý J
Cas Lek Cesk; 2006; 145(11):870-3. PubMed ID: 17168422
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
17. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients.
Amre DK; Lu SE; Costea F; Seidman EG
Am J Gastroenterol; 2006 Mar; 101(3):645-52. PubMed ID: 16464223
[TBL] [Abstract][Full Text] [Related]
18. Increased gastric and intestinal permeability in patients with Crohn's disease.
Wyatt J; Oberhuber G; Pongratz S; Püspök A; Moser G; Novacek G; Lochs H; Vogelsang H
Am J Gastroenterol; 1997 Oct; 92(10):1891-6. PubMed ID: 9382060
[TBL] [Abstract][Full Text] [Related]
19. Intestinal permeability and the prediction of relapse in Crohn's disease.
Wyatt J; Vogelsang H; Hübl W; Waldhöer T; Lochs H
Lancet; 1993 Jun; 341(8858):1437-9. PubMed ID: 8099141
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different measurements of intestinal permeability in inflammatory bowel disease.
Howden CW; Robertson C; Duncan A; Morris AJ; Russell RI
Am J Gastroenterol; 1991 Oct; 86(10):1445-9. PubMed ID: 1928036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
